Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 967-974

  Wang, Hong Gang ^a   Huang, Xiao Dan ^a   Shen, Peng ^a   Li, Lu Rong ^a   Xue, Hui Ting ^b   Ji, Guo Zhong ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

Author keywords

Epithelial mesenchymal transition; Hepatocellular carcinoma; Histone deacetylase 4; Sodium butyrate

Indexed keywords

BUTYRIC ACID; HISTONE DEACETYLASE 4; MATRILYSIN; NERVE CELL ADHESION MOLECULE; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOMA CELL; CELL CYCLE ARREST; CELL MIGRATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WOUND HEALING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTYRIC ACID; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TRANSFORMED; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HEP G2 CELLS; HISTONE DEACETYLASES; HISTONES; HUMANS; LIVER NEOPLASMS; REPRESSOR PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84875259355     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1285     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Tang ZY: Small hepatocellular carcinoma: current status and prospects. Hepatobiliary Pancreat Dis Int 1: 349-353, 2002.
3. Giannelli G, Bergamini C, Fransvea E, Sgarra C and Antonaci S: Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129: 1375-1383, 2005.
4. Marks PA, Richon VM, Miller T and Kelly WK: Histone deacetylase inhibitors. Adv Cancer Res 91: 137-168, 2004.
5. Jeon HW and Lee YM: Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression. Mol Cancer Ther 9: 1361-1370, 2010.
6. Ahn MY, Kang DO, Na YJ, et al: Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett 325: 189-199, 2012.
7. Yuan JH, Yang F, Chen BF, et al: The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma. Hepatology 54: 2025-2035, 2011.
8. Zhang J, Yang Y, Yang T, et al: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 103: 1215-1220, 2010.
9. Prasad KN: Butyric acid: a small fatty acid with diverse biological functions. Life Sci 27: 1351-1358, 1980.
10. D'Argenio G and Mazzacca G: Short-chain fatty acid in the human colon. Relation to inflammatory bowel diseases and colon cancer. Adv Exp Med Biol 472: 149-158, 1999.
11. Bergman EN: Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 70: 567-590, 1990.
12. Candido EP, Reeves R and Davie JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14: 105-113, 1978.
13. Fung KY, Cosgrove L, Lockett T, Head R and Topping DL: A review of the potential mechanisms for the lowering of colorectal oncogenesis by butyrate. Br J Nutr 108: 820-831, 2012.
14. Archer SY, Meng S, Shei A and Hodin RA: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95: 6791-6796, 1998.
15. Fung KY, Brierley GV, Henderson S, et al: Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response. J Proteome Res 10: 1860-1869, 2011.
16. Davie JR: Inhibition of histone deacetylase activity by butyrate. J Nutr 133 (Suppl 7): 2485S-2493S, 2003.
17. Sun B, Liu R, Xiao ZD and Zhu X: c-MET protects breast cancer cells from apoptosis induced by sodium butyrate. PLoS One 7: e30143, 2012.
18. Tsutsumi T, Ido A, Nakao K, et al: Reciprocal regulation of alpha-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology 107: 499-504, 1994.
19. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 76: 897-902, 1998.
20. Kaneko F, Saito H, Saito Y, et al: Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol 24: 837-845, 2004.
21. Lok GT, Chan DW, Liu VW, et al: Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells. PLoS One 6: e23790, 2011.
22. Dawson MA and Kouzarides T: Cancer epigenetics: from mechanism to therapy. Cell 150: 12-27, 2012.
23. Perego P, Zuco V, Gatti L and Zunino F: Sensitization of tumor cells by targeting histone deacetylases. Biochem Pharmacol 83: 987-994, 2012.
24. Ganesan A, Nolan L, Crabb SJ and Packham G: Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9: 963-981, 2009.
25. Quint K, Agaimy A, Di Fazio P, et al: Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 459: 129-139, 2011.
26. Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A and Ambrosio S: Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett 318: 42-52, 2012.
27. Zhang JX, Li DQ, He AR, et al: Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases. Hepatology 55: 1840-1851, 2012.
28. Wang J, Kim TH, Ahn MY, et al: Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol 41: 1101-1109, 2012.
29. Li J, Chen J, Ricupero CL, et al: Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med 18: 783-790, 2012.
30. Weems JC, Griesel BA and Olson AL: Class II histone deacetylases downregulate GLUT4 transcription in response to increased cAMP signaling in cultured adipocytes and fasting mice. Diabetes 61: 1404-1414, 2012.
31. Reddy SD, Pakala SB, Molli PR, et al: Metastasis-associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J Biol Chem 287: 27843-27850, 2012.
32. Izutani Y, Yogosawa S, Sowa Y and Sakai T: Brassinin induces G1 phase arrest through increase of p21 and p27 by inhibition of the phosphatidylinositol 3-kinase signaling pathway in human colon cancer cells. Int J Oncol 40: 816-824, 2012.
33. Catalano MG, Fortunati N, Pugliese M, et al: Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 97: E1150-E1159, 2012.
34. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
35. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell14: 818-829, 2008.
36. Iredale JP: Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117: 539-548, 2007.
37. Zeisberg M, Yang C, Martino M, et al: Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282: 23337-23347, 2007.
38. Nitta T, Kim JS, Mohuczy D and Behrns KE: Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48: 909-919, 2008.
39. Fransvea E, Angelotti U, Antonaci S and Giannelli G: Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557-1566, 2008.
40. Kaimori A, Potter JJ, Choti M, Ding Z, Mezey E and Koteish AA: Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology 52: 1033-1045, 2010.
41. Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007.
42. Cavallaro U and Christofori G: Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 4: 118-132, 2004.
43. Jovanovic V, Dugast AS, Heslan JM, et al: Implication of matrix metalloproteinase 7 and the noncanonical wingless-type signaling pathway in a model of kidney allograft tolerance induced by the administration of anti-donor class II antibodies. J Immunol 180: 1317-1325, 2008.
44. Osteen KG, Keller NR, Feltus FA and Melner MH: Paracrine regulation of matrix metalloproteinase expression in the normal human endometrium. Gynecol Obstet Invest 48 (Suppl 1): S2-S13, 1999.